1. Home
  2. PRE vs CBIO Comparison

PRE vs CBIO Comparison

Compare PRE & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$17.72

Market Cap

369.7M

Sector

Industrials

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$12.33

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRE
CBIO
Founded
2014
2003
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
369.7M
389.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRE
CBIO
Price
$17.72
$12.33
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$32.00
$27.17
AVG Volume (30 Days)
310.6K
223.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$110.85
N/A
Revenue Next Year
$64.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.09
$8.72
52 Week High
$22.86
$17.39

Technical Indicators

Market Signals
Indicator
PRE
CBIO
Relative Strength Index (RSI) 47.04 61.83
Support Level $17.00 $11.88
Resistance Level $18.48 $13.11
Average True Range (ATR) 1.95 0.88
MACD -0.56 0.42
Stochastic Oscillator 35.99 75.34

Price Performance

Historical Comparison
PRE
CBIO

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: